{"id":26278,"date":"2024-09-20T10:38:51","date_gmt":"2024-09-20T08:38:51","guid":{"rendered":"https:\/\/idibell.cat\/?p=26278"},"modified":"2024-11-21T15:28:38","modified_gmt":"2024-11-21T14:28:38","slug":"els-avencos-en-biologia-quimica-requereixen-multidisciplinarietat-i-treball-en-equip","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/09\/els-avencos-en-biologia-quimica-requereixen-multidisciplinarietat-i-treball-en-equip\/","title":{"rendered":"Els aven\u00e7os en biologia qu\u00edmica requereixen multidisciplinarietat i treball en equip"},"content":{"rendered":"

A difer\u00e8ncia de la bioqu\u00edmica, que tradicionalment estudia les reaccions qu\u00edmiques que tenen lloc en els sistemes biol\u00f2gics, la biologia qu\u00edmica \u00e9s una disciplina cient\u00edfica que se centra en l’aplicaci\u00f3 de t\u00e8cniques qu\u00edmiques i de mol\u00e8cules sint\u00e8tiques a l’estudi i manipulaci\u00f3 d’aquests sistemes biol\u00f2gics. Es considera un camp relativament nou: les publicacions de biologia qu\u00edmica m\u00e9s rellevants s\u00f3n Nature Chemical Biology, llan\u00e7ada el 2005, ACS Chemical Biology, del 2006, i Cell Chemical Biology, pionera desde 1994. Coincidint amb el seu 30\u00e8 aniversari, aquest \u00faltim acaba de publicar un n\u00famero especial que compta amb l’aportaci\u00f3 d’investigadors rellevants en la mat\u00e8ria, des de cient\u00edfics b\u00e0sics fins a cl\u00ednics.<\/p>\n

Una de persones que aporta la seva veu en aquest n\u00famero el Dr. Albert Antolin, investigador de l’IDIBELL i de l’ICO, que destaca la import\u00e0ncia de la multidisciplinarietat i el treball en equip en aquest camp. El Dr. Antolin es mostra conven\u00e7ut que “la biologia qu\u00edmica \u00e9s una disciplina cient\u00edfica nascuda de la multidisciplinarietat. Amb l’objectiu inicial d’aprofitar les tecnologies basades en la qu\u00edmica per entendre la biologia, est\u00e0 evolucionant per col\u00b7laborar cada vegada m\u00e9s amb altres disciplines, des de la ci\u00e8ncia de dades o l’enginyeria<\/em> fins a la biologia cel\u00b7lular i la recerca translacional cap al descobriment de noves ter\u00e0pies<\/em>“. Tamb\u00e9 diu que “Aquesta multidisciplinarietat \u00e9s precisament la major fortalesa del camp i el que m\u00e9s em fascina de la biologia qu\u00edmica, tot transmetent el missatge que cap disciplina individual \u00e9s millor que una altra i que els grans descobriments nom\u00e9s es produeixen quan dissolem les fronteres entre qu\u00edmics i bi\u00f2legs.”<\/em><\/p>\n

L’objectiu de la recerca del Dr. Antolin a l’IDIBELL i a l’ICO \u00e9s desenvolupar recursos p\u00fablics de biologia qu\u00edmica per millorar la reproductibilitat en biomedicina, descobrir com funcionen els f\u00e0rmacs a escala de sistema per ampliar el seu \u00fas en medicina personalitzada, desenvolupar noves estrat\u00e8gies basades en Big Data i IA per al disseny de f\u00e0rmacs multidiana i descobrir nous tractaments contra el c\u00e0ncer m\u00e9s segurs i efectius. Despr\u00e9s d’haver treballat en el sector industrial farmac\u00e8utic i el m\u00f3n acad\u00e8mic, est\u00e0 especialment interessat en la recerca translacional construint ponts entre el descobriment de f\u00e0rmacs aplicats i q\u00fcestions fonamentals encara per resoldre en qu\u00edmica i biologia de sistemes aplicada a la resoluci\u00f3 de malalties. En el seu \u00faltim estudi<\/a>, publicat a Cell Chemical Biology, ja va descobrir un potencial retargeting d’un f\u00e0rmac contra el c\u00e0ncer que podria obrir nous camins per al tractament del P\u00e0rkinson.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

El Dr. Albert Antolin, de l’IDIBELL i l’ICO, destaca la rellev\u00e0ncia de la multidisciplinarietat i el treball en equip per a l’aven\u00e7 de la recerca en biologia qu\u00edmica, un camp que est\u00e0 obrint nous camins en el descobriment de f\u00e0rmacs i la medicina de precisi\u00f3.<\/p>\n","protected":false},"author":8,"featured_media":26279,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452,519],"tags":[],"class_list":["post-26278","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-de-mama","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure","category-quimica-medica-i-disseny-de-farmacs"],"publishpress_future_action":{"enabled":false,"date":"2024-12-01 03:28:59","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26278"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26278\/revisions"}],"predecessor-version":[{"id":26280,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26278\/revisions\/26280"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26279"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}